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Abstract
Mousumi Akter Sumi
EXPERIMENTAL PHARMACOTHERAPIES IN MODELS OF ALCOHOL
ADDICTION
2019-2020
Thomas M. Keck, Ph.D.
Master of Science in Pharmaceutical Sciences

The USA faces $220 billion economic loss and eighty thousand deaths per year due
to alcohol abuse while affecting more than 15 million people, making it the third largest
life-style related cause of death. The U.S. FDA has approved four medications namely,
disulfiram, acamprosate, oral naltrexone, and injectable long-acting naltrexone. These
existing drugs are trashed with side effects, have a low success rate, indicating a demand
for new potential drugs. We studied the effects of the CB1 negative allosteric modulator,
PSNCBAM-1, and the dopamine D4 receptor antagonist, L-745,870 in mouse models of
alcohol addiction. PSNCBAM-1 did not significantly reduce CPP for 2.0 g/kg ethanol or
alter locomotor activity, but its dose-dependently attenuated oral ethanol selfadministration at the dose of 30 mg/kg. 18 and 30 mg/kg PSNCBAM-1 significantly
reduced self-administration of palatable food reward. These results suggest, PSNCBAM-1
produces a non-specific anhedonic effect that may preclude its use in AUD. L-745,870 did
not significantly affect conditioned place preference for 2.0 g/kg ethanol, ethanol selfadministration, locomotor activity in an open field, or co-ordination in the rotarod test.
These results suggest that D4R antagonism does not alter the rewarding value of ethanol.
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Chapter 1
Introduction
What is Ethanol?
Ethanol (C2H5OH) is a type of alcohol used extensively in foods, beverages,
pharmaceuticals, chemical syntheses, and more (Pohanka, 2016). It is an organic
compound characterized by its colorless nature, volatility, flammability, and water-soluble
nature, with a slight chemical odor (Levy, 2020). The chemical structure of ethanol is
shown below in Figure 1.

Figure 1. Structure of ethanol. The ingredient in beverages, food, pharmaceuticals, etc.

Preparation of Alcohol
Ethanol can be naturally manufactured using the fermentation protocol for certain
carbohydrates, namely sugars, starches, or synthetically, using ethylene's chemical
hydration. (Weathermon & Crabb, 1999). Ethanol production as alcoholic beverage using
the fermentation process has been practiced for centuries. It is difficult to determine when
humans first learned to produce alcohol, but one of the most widely known alcoholic
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beverages, wine, is thought to have been produced in ancient Greece and China, in the
same time period when iron was discovered (Pohanka, 2016). The chemical formula for
the fermentation of ethanol can be seen that is presented in Figure 2 below.

Figure 2. The fermentation process of alcohol in which yeast ferments the sugar (in this
case the disaccharide sucrose) in fruit and grains into ethanol and carbon dioxide.

Why Alcohol Consumption
The most common reason for alcohol consumption is its mind-altering properties,
including its ability to alter mental and emotional states via actively inducing euphoria,
relaxation, disinhibition, and suppressing stress and anxiety. (Gilman, Ramchandani,
Davis, Bjork, & Hommer, 2008).
Alcohol Pharmacology
Pharmacologically alcohol can be characterized as a γ-aminobutyric acid (GABA)
and serotonin agonist that contains a number of neurotransmitter receptors located in the
2

brain, altering the nature of permeability of various ions namely, Cl–, K+, Na+, or Ca2+
through the help of their respective channels, i.e., enhancing the passage of Cl– ions through
GABA-A channels, and suppressing the passage path of Na+ and Ca2+ through N-methyl
D-aspartate (NMDA) and non-NMDA channels (Albanese, 2012). These processes
eventually cause upregulation of dopamine release in the ventral tegmental area of the
midbrain and dopamine release in the nucleus accumbens that enhance pleasurable
sensations and euphoria (Friedlander, Marder, Pisegna, & Yagiela, 2003; Gessa, Muntoni,
Collu, Vargiu, & Mereu, 1985).
Ethanol is actively absorbed into the systemic circulation via the mucous
membranes of the mouth, stomach, small intestine, and colon (Weathermon & Crabb,
1999). Once it is absorbed, alcohol is consequently transported to the liver via the portal
vein. A portion of the administered alcohol is metabolized during its primary passage
through the liver; the remainder of the administered alcohol exits from the liver, enters into
the systemic circulation and is finally distributed throughout the entire body tissues
(Weathermon & Crabb, 1999). The concomitant intake of various kinds of foods with
alcohol generally results in a diminished area under the curve (AUC) on a blood alcohol
concentration (BAC) curve, in addition to a lower peak concentration and an elevated time
to reach the peak BAC (Sedman, Wilkinson, Sakmar, Weidler, & Wagner, 1976).
Essentially, an expanded threat for heavy drinkers and a relatively lower threat for
lighter alcohol drinkers results in the ‘J’-shaped alcohol-mortality curve (Klatsky,
Friedman, Armstrong, & Kipp, 2003). Not to mention, an unbiased view of alcohol
drinking and health should always consider its deleterious and helpful implications, amount
of alcohol taken, choice of beverage, and last but not least, drinking patterns (Klatsky et
3

al., 2003). Having profound impact on mood and mental state, alcohol is one of the most
widely known psychoactive substances that is produced by yeasts that digest the sugar in
certain carb-rich foods, like grapes are used to make wine, or grains are used to produce
beer (Steele & Josephs, 1990).
Negative Health Effects of Alcohol Consumption
The consequences of excessive alcohol use in terms of health risk is huge. The USA
faces $220 billion in economic losses and eighty thousand deaths per year due to alcohol
abuse, which makes it the third largest life-style related cause of death. (Yeligar et al.,
2016)
The excessive use of alcohol is closely related to an enhanced risk of various
physical injuries and accidents. Even a single dose of excessive drinking can possibly bring
about moderate to severe negative consequences. In a broad sense, alcoholism and chronic
use of alcohol are linked to various medical, psychiatric, social, moral, and family
problems. Children in families who are exposed to a first-degree relative's alcohol
addiction are at risk. Children of parents with alcohol dependence have shown a higher
degree of alcoholism than children who do not have parents with alcohol dependence.
Nowadays, alcohol dependence related violence has become a serious social phenomenon
where we observe more violent behavior in alcohol-dependent individuals (Heinz, Beck,
Meyer-Lindenberg, Sterzer, & Heinz, 2011). It is extremely significant for social workers
to bear in mind that alcohol and alcohol-related problems largely affect human health,
safety, and well-being (Moss, 2013).
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Physiological Systems Affected by Alcohol Abuse
Several physiological systems are potentially harmed by long-term, excessive alcohol
use (Albanese, 2012). Firstly, the central nervous system (CNS) is mostly affected by many
psychiatric problems. Alcohol abuse is known to cause various disorders, including
peripheral neuropathy, reduced sleep latency, Wernicke-Korsakoff syndrome, blackouts,
dementia, cerebellar degeneration, and so on (Fitzpatrick, Jackson, & Crowe, 2008;
Hariharan, 2013; VITIELLO, 1997). Secondly, the gastrointestinal tract is affected by
diseases like elevated gastric acid secretion, esophagitis, enteritis, gastritis, etc. (Bode &
Bode, 1997). Alcohol abuse also lowers the esophageal sphincter tone, increases the
absorption process of iron, slows down the absorption of some vitamins, increases toxicity
to pancreatic cells, elevates the likelihood of various cancers, including gastric, esophageal,
hepatocellular, pancreatic, and colorectal cancers (Albanese, 2012). Fatty liver and liver
cirrhosis are also an outcome of the gastrointestinal tract being affected by excessive
alcohol consumption (Diehl, 2002).
Thirdly, hematopoietic systems are also affected by alcohol abuse, which results in
pancytopenia, increased mean corpuscular volume (MCV), and toxic granulocytosis
(Heermans, 1998). Fourthly, alcohol abuse affects cardiovascular systems by increasing
high-density lipoprotein (HDL), decreasing myocardial contractility and peripheral
vasodilatation, decreasing blood pressure (BP) in small doses, though BP is enhanced when
used for long-term in high doses (Zakhari, 1997). Additionally, cardiomyopathy and
arrhythmias are also outcomes of excessive alcohol intake. Fifthly, genitourinary tract modest doses potentially increase sex drive but reduce erectile capacity, sometimes
testicular atrophy with shrinkage of the seminiferous tubules, responsible for amenorrhea,
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and decreased ovarian size, infertility, and consequentially, spontaneous abortions (Havers,
Majewski, Olbing, & Eickenberg, 1980). Lastly, other body systems affected by alcohol
abuse are known to cause fetal alcohol syndrome, alcoholic myopathy, osteonecrosis with
elevated fractures, avascular necrosis of the femoral heads, and reversible decreases in T3
and T4 hormones (Albanese, 2012).
History of Alcohol Use
The history of using alcohol dates back thousands of years. Even prehistoric people
used alcohol for different purposes, but many of those were unknowingly done. Although
procedures to produce alcohol and related beverages have transformed in some way over
the years, very little has changed from the basic. Dating back from the prehistoric ages, the
idea of taking alcohol to swing human mood and behavior is not very new at all (Albanese,
2012). The ninth chapter of the two thousand years old Biblical book of Genesis tells a
story of Noah, where the most righteous man on earth became drunk. The first actual
evidence of alcoholic drinks production dates back around 8000 B.C., after humans have
started agriculture and started to establish sedentary communities (Khaderi, 2019). The
oldest evidence of alcohol comes from chemical analysis of residues inside pottery jars
found in Jiahu located at North China (McGovern et al., 2004). Dating back to 7000 to
6600 B.C., these clay pots help a fermented drink made from rice, honey, grapes, and
hawthorn berries (Lee et al., 2009). Since then, different kinds of fermented grains, fruit
extracts, and honey have been successfully used to manufacture alcohol for thousands of
years.
Different kinds of beer were produced in ancient Egypt (A. H. Joffe, 1998). The
reliable evidence for most was the fermentation of wheat or barley, triggered by malting,
6

efficient manipulation of germinated grains as a source of enzymes to transform
carbohydrates into sugars, further intensified by elongated heating, and finally flavored by
adding dates, fruits, and wines (Darby, 1977; Gastineau, Darby, & Turner, 1979). The
Levantine Early Bronze Age, which was thought to be between 3500–2350 B.C.,
experienced the uprising of a small-scale urban civilization when the production of wines
and oils became a key focal point for the new emerging economy (Esse, 1991; A. Joffe,
1993). Most of the manufacturing of wines, oils, and vessels in the Levant appears to have
been incorporated for intrasocietal use, distribution and consumption. Different kinds of
ceramic pots from the Mesopotamian civilization suggests that manufacturing and intake
of alcoholic beverages enhanced extensively throughout the 4th and 3rd millennia (A. H.
Joffe, 1998). The considerable rise in workshop-produced spouted jars and flasks in the
Uruk-period certainly suggests increased use of beverages produced and stored in closed
vessels (Delougaz, 1952; A. H. Joffe, 1998). The gradual evolution of alcohol use and
consumption patterns in India can be roughly divided into four broad eras; it began with
the Vedic era (ca. 1500–700 B.C.) (Sharma, Tripathi, & Pelto, 2010). From 700 B.C. to
1100 C.E., is the time of emergence and flourishment of Buddhism and Jainism, with some
new anti-alcohol doctrines within the religions, and the post-Vedic cultures in the Hindu
traditions and its scholarly writing and documents (Sharma et al., 2010). The writings of
the two famous traditional medical practitioners, Charaka and Susruta, added a new era of
thought, where they added arguments titled “moderate alcohol use” for particular health
benefits (Sharma et al., 2010).
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Alcohol as Medicine Through History
Throughout human history, the use of alcohol is established with numerous
complications, including social norms, culture, rituals, religion, economics, traditions,
medical beliefs, fun times, gatherings, and perhaps much more. The therapeutic use of
alcohol with different medications appears to be as old as alcohol.
Rice wines and herbal remedies in Ancient China. Alcohol-based herbal
medicines encompass a major portion of almost all Chinese works on herbal prescriptions
and medicine, and on a general level, alcohol was thought to promote blood warming and
blood revitalization (Nunn, 1996). Chinese medical literature also refers to some
circumstances that necessitate alcohol quantities to be imbibed and discusses the adverse
outcomes of its excessive use (Nunn, 1996).
Beer and wine in Pharaonic Egypt. Dating back to nearly 3400 B.C., the most ancient
known brewery is thought to have been situated at Nekhen (also known as Hierakonpolis)
in Egypt. Brewing was considered a very sophisticated art then, in Pharaonic Egypt, and
beer was then also known as "necessity of life," was very popular among mass people.
Osiris, known as the God of life and death, was the God of wine at the same time, which
was largely imported for the people of upper classes. The intake of alcohol was extensive
than and generally used for "pleasure, nutrition, medicine, religious purposes, gifts, and
funereal purposes" (Hanson, 2013; Murray, 1999).
Wine and sophistication in Classical Greece. The wine was considered as an
effective therapeutic agent for both body and the mind, for both men and women, was
largely prescribed by the then physicians in classical Greece for ailments like bad breath,
cancer, and wound healings, or to "loosen bowels" (Hanson, 2013; Links, PRO, Start, &
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by Step; Villard, 1997). Even Hippocrates considered wine an efficient remedy for various
disease conditions except for those involving "an overpowering heaviness of brain"
(Hanson, 2013). According to their judgment, the wine had an active role in disease
pathology and treatments (Links et al.; Villard, 1997).
Wine remedies and binging in the Roman Empire. The utilization of wine as a
remedy in the ancient Roman Empire was mostly guided by Greek and Etruscan
traditions (Faria, 2015). The Romans used to make a composition of wine and frankincense
or myrrh to mask the muscle senses before any surgery, a practice thought to derive from
the Talmudic medicine system (Links et al.). The widespread intake of wine for various
purposes, mostly for sustenance and pleasure, mainly increased in the second century B.C.
and, with the further extension of the great empire, the usage of wine spread very far and
wide (Brownlee, 2002). Probably for the first time in history, binge drinking turned into a
popular drink in leisure hours.
The water of immortality in the middle ages. During the Middle Ages, brewing was
one of the major occupations for many people throughout entire Europe for monasteries
and religious rituals (Links et al.). Among the brewed goods, beer was a vital source of
sustenance: between 1000 and 1500 A.D., the average adult population in England is
thought to have taken approximately 1 gallon of it per day (Barr, 1999; Links et al.). At
that time, physicians and local practitioners continued to believe in the therapeutic values
of alcohol, including those of new distilled concoctions, as for example, aqua vitae, also
then known as “divine medicament” (Hanson, 2013). During the eighth and ninth century
in Poland and Russia, an alcoholic drink, named vodka, made from fruit, herbs, spices,
wormwood, acorn, birch, chicory, sorrel, dill, horseradish, mint, lemon, was highly
9

regarded for its estimated therapeutic values (Barr, 1999). One of the famous ancient
physicians, Arnaldus de Villanova, took aqua vitae as a "cure for all ailments," which was
effective against general fevers and other cold diseases and prophylaxis against the everpresent life-threatening plague disease (Berdan & Anawalt, 1997; Links et al.).
Pulque, mead, and maize-based alcohols in Mesoamerica. The widespread
consumption of alcohol includes ancient societies in Mesoamerica. Evidence suggests that
Mayans brewed mead and maize-based alcohol around 1000 B.C. in ancient Mesoamerica
(Gately, 2008). Alcohol was extracted from cacti, fruits, and barks, as found in surviving
artifacts and in many Spanish historians (Hanson, 2013). Therapeutic use of alcohol is
believed to have been rampant in the age of pre-Columbian Americas, differing with the
position in societies and cultures (Hanson, 2013).
A question of dosage. During the Renaissance and Enlightenment period, there was a
deeply rooted belief in beer and wine's restorative and therapeutic potentials despite having
ample anatomical understanding. In those years, alcohol was frequently prescribed in the
London hospitals, but eventually, with a considerable rise in medical knowledge, growing
disbelief was found among medical practitioners and general people about the role of
alcohol in health promotion (Hanson, 2013). Although more knowledgeable and
sophisticated medical personnel began to question the role of alcohol-based folk medicines,
a child named David Hume was cured with drink therapies for his nervous problem. Hence,
alcoholic drinks were still in the prescription for children in several illnesses (Hanson,
2013). During that period, tea imported from Asia started to achieve more traction as a new
panacea, which was probably superseding alcohol as the new miracle of cure to all ailments
(Hanson, 2013).
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The gin crazes. Among the starting seeds of new transformation brought to England
from Holland by King William, a brand new alcoholic drink, popularly known as distilled
juniper water ("geneva" or "gin"), which was essentially an ideal tonic for the ailments of
the stomach, gout, and gallstones, kidneys, liver, and heart (Berdan & Anawalt, 1997).
According to the renowned Irish physician Dr. Robert Bentley Todd, a medical professor
at King's College in London, it certainly helped natural disease healing processes in
humans (Barr, 1999).
Mint julep, cocktails, and tonics in the United States. The mint julep, an
amalgamation of mint and whiskey, and probably the ancestor of the modern known
cocktail was first invented in the southern United States during the 18th century. It was
given to the patients by some practitioners as a treatment for "all sorts of pathological
conditions and ailments of the southern climate" (Berdan & Anawalt, 1997). As a tonic or
a possible cure to all, mint julep was mostly a part of a wave of pseudo therapeutic drinks
familiar as "cordials," "patent medicines," and "stomach elixirs," often used extensively to
"treat women's constitutions." Other popular tonics of that time, such as, less cocktail than
medicine and often sold as an alcohol-free drink, like Parker's Tonic, that contained 42%
alcohol; Dr. Kaufmann's Sulphur Bitters, which contained 26% alcohol; Dr. Hoofland's
German Bitters, that had 26% alcohol; Whiskol with 28% alcohol; Colden's Liquid Beef
Tonic with 27% alcohol; and Lydia E. Pinkham's Vegetable Compound for “female
complaints” (Berdan & Anawalt, 1997).
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Prohibition and the winds of change. The extensive use of alcohol for medical
purposes brought about division in the medical profession in the early days of the 20th
century. In the absence of other remaining options, it was in some circumstances used as
medication during the Spanish influenza epidemic in 1920 and as a treatment for
pneumonia (Berdan & Anawalt, 1997). Nonetheless, an ever-growing awareness about the
adverse effects of its abuse fueled the claim for a total and widespread ban of alcohol,
leading to its prohibition in many countries, such as Russia (1916-1917), Norway (19191927), Finland (1919-1932), and the United States (1920-1933) (Links et al.). In the United
States, alcohol with medicinal values reached a higher new level during the tumultuous
prohibition years. US doctors were permitted for 100 prescriptions for "medicinal whisky"
per three months span, which in total amounted to about 1.8 million gallons of alcohol in
the year 1927 (Barr, 1999).
The Historical and Cultural Relevance of Alcohol
The craving for alcohol differs from men to men, and certainly, ethnicity, race,
gender, etc. have essential roles to play here. Throughout the world, men drink more
alcohol than women, and women in relatively more developed countries consume more
alcohol than women in relatively less developed countries (Rehm et al., 2009). In contrast
with men, more women are lifetime abstainers of alcohol, consume less, and are less prone
to fall into drinking disorder and alcohol withdrawal symptoms (Erol & Karpyak, 2015).
Misuse of alcohol is a burning health problem, especially among the youth, which often
leads to severe consequences. Not to mention, identifying factors in the religiosity-alcohol
relationship has vital implications for the intervention development process (Hai, 2019).
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Alcohol and Ethnicity
Along with religious influence, the role of diversified cultural norms and social beliefs
can’t be ignored when predicting current drinking patterns and frequency of heavy drinking
(Brooks-Russell, Simons-Morton, Haynie, Farhat, & Wang, 2014). Across all races and
ethnicities, conservatism about drinking is observed more among the African-Americans
and Latinos than the Whites (Caetano & Clark, 1999). Adolescents, passing more times
with their friends than with their families, are more frequently involved in heavy drinking.
Alcohol and Sociocultural Influence
Studies have also pointed out the parents who are highly involved in heavy drinking
increase the possibility of their children getting involved in regular alcohol intake (Caetano
& Clark, 1999). Media have a huge role in regulating the rate of alcohol consumption
within a society. TV advertisements, movies, TV series, various social media platforms,
etc. bear a significant influence in setting alcohol usage patterns within a society. Every
day, people view a considerable number of TV advertisements on alcohol and related
beverages, despite the fact that alcohol marketing is greatly regulated by most countries
(Grenard, Dent, & Stacy, 2013). Several socio-cultural influencers estimate the prevalence
of alcohol consumption, including social discrimination and associated stigma. The huge
role of discrimination and mental and physical stress in health-associated risk behaviors,
including alcohol abuse, is very well rooted in liquor advertisements, especially in the US
(Dawson, Grant, & Ruan, 2005; Sudhinaraset, Wigglesworth, & Takeuchi, 2016).
Government Regulation
After the tobacco and obesity problem, the overconsumption of alcohol is the third
largest cause of death in the United States. Moreover, the death rate because of alcohol
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abuse has nearly doubled in recent years, which includes premature deaths that are
associated with alcohol abuse, such as motor vehicle accidents. Heavy drinking habit
worsens the morbidity rate among the mass population. It can cause various chronic
diseases, including hypertension, hepatitis, diabetes mellitus, etc. Heavy drinking habit is
certainly a problem for those who usually administer different types of medicines daily.
Drug metabolism and its therapeutic efficacy are greatly hampered by alcohol present in
the stomach. Societal costs of over alcohol consumption have far-reaching consequence,
including increased rate of severe alcohol injury, accidental deaths in roads and highways,
income loss, wastage of the country’s healthcare resources, and disruption of social and
family life (Bouchery, Harwood, Sacks, Simon, & Brewer, 2011).
Since chronic alcohol consumption is the burning issue, the National Institutes of
Alcohol Abuse and Alcoholism (NIAAA) has published a guideline for acceptable upper
limits of alcohol consumption by adults. According to the NIAAA, men aged 21–65 should
take a maximum of fourteen standard drinks per week and four standard drinks per day.
The rules for women and older adults are a bit different. Adult women (age 21–65) and
older adults (aged over 65) should not take more than seven standard drinks per week and
three standard drinks per day.
All the standard drinks have the same percentage of alcohol, which is less harmful
to human physiology. But, it is true that the percentage of alcohol in the standard drinks
and guided upper limits differ from state to state (Suzanne & Kril, 2014). In the United
States, a standard drink contains 14 g of alcohol. Among the standard drinks, 355 ml of
beer, 237 ml malt liquor, 148 ml wine, 44 ml 80-proof spirits are mentionable which
contain 5, 7, 12, and 40 % of alcohol, respectively (Kalinowski & Humphreys, 2016;
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Miller, Heather, & Hall, 1991; Turner, 1990).In Australia and New Zealand, a standard
drink is defined as 10 grams of ethanol and four drinks per day, and 14 drinks per week are
the upper limit of drinking. In Japan, a standard drink is allowed to bear 19.75 grams of
alcohol, whereas a standard drink contains 8 grams of alcohol in the United Kingdom. In
the European Union countries, the alcohol content in a standard drink differs from country
to country, ranging from 6 to 17 grams of alcohol in alcoholic drinks. Among most of the
guidelines, it is recommended that pregnant and breastfeeding women should abstain from
consuming alcohol (Bouchery et al., 2011).
Pharmacokinetics
Distribution. Ethanol is reasonably insoluble in fatty materials, yet it can surpass the
mammals' biological membranes as water does. Essentially, ethanol evenly circulates into
the blood via absorption from the gastrointestinal tract, then passes into all body tissues
and other body fluids via a consistent ratio with their comparative water content. The active
concentration of ethanol within body tissues heavily relies on the relative water content of
the tissues. It swiftly reaches the equilibrium condition in relation to ethanol concentration
in the body plasma (Frezza et al., 1990). But alcohol does not bind to any plasma proteins.
Dose-response mechanisms for alcohol consumption for different individuals vary largely.
The same amount of alcohol dose per unit of body weight can exhibit quite different bloodalcohol concentrations in different individuals, mostly because of variations in fat ratios to
water in different bodies and low lipid: water partition coefficient of ethanol within the
bodies (Cole-Harding & Wilson, 1987). Women's physiological condition generally shows
relatively a smaller volume of distribution for alcohol than men, mainly because of their
larger percentage of fat present in the body. Alcohol first-pass metabolism is generally
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more significant in males than females, which also influences the higher concentration of
alcohol in blood, particularly in females (Cole-Harding & Wilson, 1987; Frezza et al.,
1990).
Absorption. Alcohol absorption is quicker in the duodenum and jejunum than in
the stomach; therefore, the rate and prevalence of gastric emptying time is a vital
determinant factor in terms of the rate of absorption of orally administered alcohol
(Halsted, Robles, & Mezey, 1973). Alcohol can pass through the biological membrane
barriers via the passive diffusion method down towards its concentration gradient. Hence,
a higher concentration of alcohol results in a larger concentration gradient of alcohol and
faster absorption. Alcohol is also known for its irritant properties, and higher
concentrations of alcohol can result in superficial tissue erosions, hemorrhages, and
insensitivity of the smooth muscle cells in the stomach. This incident is responsible for
reducing alcohol absorption. Blood alcohol concentration is generally higher if ethanol is
consumed as a single dose rather than several tiny doses, perhaps because the concentration
gradient of alcohol will be greater in the previous case. Different alcoholic beverages
containing the same amount and concentration of alcohol are expected to be continuously
absorbed. That's why the blood alcohol concentration remains all the same after
administering different types of alcoholic beverages with the same concentration of alcohol
(Baraona et al., 2001; Kwo et al., 1998; Wilkinson, Sedman, Sakmar, Kay, & Wagner,
1977). Stomach filled with foods certainly delays the gastric emptying time, and that's why
it decreases the absorption of alcohol and supports the concept that “Don't drink on an
empty stomach” (Moxnes & Jensen, 2009).
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Metabolism. The major enzyme systems that are involved in the oxidation process of
ethanol, among them alcohol dehydrogenase and cytochrome P450-dependent ethanoloxidizing system, are abundantly in the liver (Morgan & Levine, 1988). Most of the
consumed ethanol in the body is metabolized in the liver by a specific enzyme named
alcohol dehydrogenase, which converts ethanol into a toxic metabolite called acetaldehyde
(CH3CHO), a well-known carcinogenic agent. But acetaldehyde is normally a short-lived
compound; it is consequently converted into a comparatively less toxic compound, named
acetate (CH3COO-) through interference from an enzyme called aldehyde dehydrogenase.
Acetate is then further converted into carbon dioxide and water, mainly in tissues except
for the tissues in the liver (Alert, 2007).

Elimination. Alcohol elimination is a zero-order kinetic process that certifies that
alcohol is eliminated from the body at a constant rate. Elimination of alcohol from the body
occurs principally via enzymatic oxidation in the liver, with usually minor non-hepatic
oxidation pathways and minor excretion of unchanged alcohol in the urine, breathe, and
perspiration (Dubowski, 1985).
Introduction Alcohol-Use Disorders (AUDs)
The very term "alcohol-use disorders" basically consists of long time alcohol
dependence and alcohol abuse or excessive use (Association, 2000). According to U.S.
Department of Health and Human Services, AUD is a medical diagnostic state that can be
characterized as a chronic relapsing brain disease described by uncontrollable alcohol use,
loss of self-regulation over alcohol consumption has a negative and depressing mental state
when not consuming alcohol. Alcohol overconsumption and its related toxicities are
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responsible for nearly eighty-eight thousand deaths per year in the United states (K
Witkiewitz, Litten, & Leggio, 2019). AUD is such a sort of psychiatric problem which
affects approximately one-third of the US adult population at some point in their life span.
In addition to health risks, AUD costs the United States nearly $249 billion per year (K
Witkiewitz et al., 2019). However, it is a matter of joy that recent advances in medical
treatment patterns have helped patients manage AUD. Although various researches during
the last one or two decades have enlarged the understanding of AUD on a broad level, more
research is necessary at the same time to identify the etiological and treatment-related
influencers of this disease (K Witkiewitz et al., 2019).
The important influencers under study include genetic, neurobiological, epigenetic,
psychological, social, and environmental factors. It is most significant to implement this
research-based knowledge in different clinical practice layers to ensure efficient diagnosis
and treatment of AUD. As far as AUD and its consequences are concerned, these lifethreatening disorders mimic and exacerbate a large variety of additional medical and
psychiatric complexities and compress the lifespan of the addicted people (Schuckit, 2006).
However, a big problem within this reality is, most people suffering from AUD are difficult
to identify since they are likely to be involved in jobs, families, and daily life and generally
present with symptoms including anxiety, malaise, sadness, insomnia, etc. (Organization,
1993).
History of Treatment for AUD
A physician from Pennsylvania named Benjamin Rush first talked about the
possible treatment patterns of alcohol abuse during the edge of the 18th century (Rush,
1823). He studied different cases after cases and eventually came up with some possible
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ways to manage AUD. He emphasized the practice of religion strictly, which might help
people to realize guilt and shame. The physician also suggested giving much importance
to personal passions and likings, while a person's diet would only include vegetarian foods
(Rush, 1823). During the last two centuries, it is extensively preached by many social and
voluntary assistance groups that over alcohol consumption is an ethical failure. We can
also find traces of some permanent and temporary asylums to provide house treatments to
alcohol-addicted patients during the same era. Though these asylums only ensured forced
abstinence from alcohol consumption (Baumohl, 1990). An organization named
“Alcoholics Anonymous” was found in the year 1935 with a view to restricting people
from alcohol consumption through motivations and different processes (White & Kurtz,
2008). The idea of AUD first emerged in the 1940s; consequently, various treatment
options were invented, some of which have been practiced for so long and exist even today
(Jellinek, 1942). According to the World Health Organization’s Global Status Report on
Alcohol and Health-2018, we have observed enforcement of several public health policy
initiatives, including increased taxation on alcohol sales, restrictions on advertising of
alcoholic drinks, and brief scale intervention programs, such as revitalization of social
norms and rules that can help control the abundance of AUD.
The Broader Impact of AUD in Society
Till today, AUD is socially regarded as a personal lousy habit or fault rather than a
disease. To some particular extent, this judgment is winning the public opinion as well as
among the health care providers (Neuberger, Adams, MacMaster, Maidment, & Speed,
1998). But it is also to acknowledge that public perception has started to change among the
mass population due to widespread education campaigns. Today, it is accepted that
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alcoholism is a disease (Gitto, Vitale, Villa, & Andreone, 2014). Thus, AUD is largely
regarded as a clinical circumstance related to a substantial amount of disability and loss of
quality of life (Samokhvalov, Popova, Room, Ramonas, & Rehm, 2010). Not to mention,
alcoholism is one of the main reasons for frequent road accidents and many other social
violence episodes (Mathurin & Bataller, 2015).
Classification of AUD
Patients having AUD can be classiﬁed based on the craving pattern for alcohol (Sinha
& O'Malley, 1999). Alcohol craving is vitally responsible in AUD that broadly impacts the
pharmacological and physiological choice and the principal prognosticator of alcohol
addiction (Addolorato, Abenavoli, Leggio, & Gasbarrini, 2005). AUD can be classified
into the following categories: (a) reward craving (due to family history of alcoholism
involving the loss of regulation of dopaminergic or receptors and representative personality
characteristics); (b) relief craving (due to deregulation of GABAergic or glutamatergic
receptors); (c) obsessive craving (involves deregulation of serotoninergic receptors, typical
personality traits consisting of the absence of alcohol inhibition, compulsive drinking
pattern, loss of control on alcohol consumption, and alcohol-related impairment)
(Addolorato, Leggio, Abenavoli, Gasbarrini, & Group, 2005). Although it has to be
mentioned that “The Craving Typology Questionnaire" is not yet considered an
authenticated diagnostic aid that can classify patients by their craving typology for alcohol
(Martinotti et al., 2013).
Biological Mechanisms Underlying AUD: Focus on GABA Receptors
The biological pathways of AUD are yet incompletely understood. Alcohol intake has a
powerful impact on brain functioning and behaviors (Bayard, Mcintyre, Hill, & Woodside,
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2004). Continued over alcohol intake can gradually build up a physical dependence on
alcohol for a considerable amount of time. In that case, discontinuation or abruptly
decreased alcohol intake stimulates AWS4 (alcohol withdrawal syndrome). Today, the
pathways for how excessive alcohol intake guides physiological changes in the human
brain functioning that generate alcohol dependence prevail quite dark. AUD is a long-term
generation process, and thus it is characterized as a chronic disease. For instance, a relapse
in alcohol intake might be voluntary and spontaneous. Various intrinsic stimuli inside the
body, such as anxiety, mood swing, etc. can cause a relapse.
Some external factors like drinking culture in the family and society or even the
bottles of alcoholic drinks can cause a relapse. Regardless of both of this view-point, the
profound impact of alcohol on the human brain and nervous system cannot be overlooked
by any mean, provided lot of neuropharmacological and psychological impacts of ethanol,
including its sedative, anxiolytic, intoxicating, reinforcing, and addictive potentials
(Hobbs, 1996; Paul, 2006).
GABA is one of the main inhibitory neurotransmitters located in the mammalian
brain systems. A GABAergic neuron triggers an action potential, and then the presynaptic
nerve terminus helps to release GABA into a synaptic cleft. GABAARs are a family of
ligand-gated chloride anion route communicated throughout the entire central nervous
system and consist of five subunits along with several isoforms, namely, α1−6, β1−3, γ1−3,
δ, ε, θ, π, ρ1−3 (Nayeem, Green, Martin, & Barnard, 1994) (Barnard et al., 1998;
Macdonald & Olsen, 1994; Nayeem et al., 1994; Olsen & Sieghart, 2008, 2009).
GABA attaches to the GABAARs, altering their conformational systems and
consequently unfolding the pore to permit the passage of chloride (Cl−) ion to move down
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towards an electrochemical gradient. GABAARs induce fast and phasic inhibition in the
postsynaptic membrane. The metabotropic GABABRs slow down the synaptic inhibition.
GABAARs are known to induce several pharmacological impacts of alcohol in the brain.
Evidence shows that GABAARs are the main target of ethanol in the CNS (Becker, Veatch,
& Diaz-Granados, 1998; Boehm II et al., 2004; Koob, 2004; Olsen & Spigelman, 2012;
Weiner, Zhang, & Carlen, 1994). Several studies have demonstrated that alcohol
consumption for a shorter duration of time upregulates the GABAARs inhibitory effects.
Yet, many more factors decide whether GABAARs would respond to alcohol exposure for
a short duration or not (Mihic & Harris, 1997). Alcohol can function as a depressant by
upregulating

inhibitory

neurotransmission,

and

by

downregulating

excitatory

neurotransmission, or via a combination of the both (Lithari et al., 2012; Valenzuela, 1997).
In general, alcohol intake can affect mental attention, alter memory functions,
reduce executive decision-making capability, change the mood, and cause drowsiness.
GABAARs are known to mediate sedation, anxiolysis, inconsistency in motor
coordination, and withdrawal symptoms, including hyperexcitability, anxiety, insomnia,
and random seizures (Buck & Finn, 2001; Buck & Reynolds, 1996; Davies, 2003; Grobin,
Matthews, Devaud, & Morrow, 1998; Hanchar, Dodson, Olsen, Otis, & Wallner, 2005;
Kumar et al., 2009; Liang, Cagetti, Olsen, & Spigelman, 2004; Liang, Spigelman, & Olsen,
2009; Rudolph & Knoflach, 2011; Tobler, Kopp, Deboer, & Rudolph, 2001). Ethanol
works on some specific sub-groups of GABAARs, and their subunit assembly is swiftly
altered, which subsequently changes the functional characteristics of these GABAARs
(Grobin et al., 1998; Kang, Spigelman, Sapp, & Olsen, 1996). Consequently, GABAARinduced behaviors are altered after alcohol consumption (Cagetti, Liang, Spigelman, &
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Olsen, 2003; Liang et al., 2004; Liang et al., 2009). Evidently, it can be stated that
GABAARs have a pivotal role in response to ethanol, thereby modulating the altered
balance between inhibition and excitation and contributing largely to the withdrawal
syndrome.
Types of Treatment
As alcohol abuse is a long-existed problem on this planet, there was always an
attempt within many human societies to resolve this issue. Woods, leaves, and barks from
various trees were used to contain the habit of over alcohol consumption among mass
people. Several treatment approaches have been attempted so far to treat people having
AUD. Proper and sustained treatment of alcohol use disorders mainly depends on its proper
and early diagnosis and understanding of the fact that there exists a wide spectrum of
drinking disorders.
Pharmacologic Therapies Approved by the U.S. Food and Drug Administration
So far, the U.S. Food and Drug Administration (FDA) has approved four medications
for the treatment of alcohol use disorders. The medications are disulfiram, acamprosate,
oral naltrexone, and injectable long-acting naltrexone.
Disulfiram. Disulfiram (Antabuse™) is the first medication for AUD approved by
the FDA in 1948 (Liang & Olsen, 2014). It is an anti-craving drug that blocks
acetaldehyde's transformation into acetate by the aldehyde dehydrogenase enzyme.
However, disulfiram causes some side effects like headache, nausea, flushing, vomiting,
flushing, etc. when taken simultaneously with alcohol consumption. That’s why there is a
black box warning for disulfiram intake, which says it should not be prescribed to patients
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who have administered alcohol during the last 12 hours. This drug's dose range is 125 to
500 mg/d, although the higher dose range is possible at high dosing intervals. Recent
reports have demonstrated that this drug has only a moderate short-term reduction capacity
in alcohol use (Jørgensen, Pedersen, & Tønnesen, 2011). The chemical structure of
Disulfiram is shown below.

Figure 3. Structure of Disulfiram. One of the first FDA approved medications for the
treatment of AUD.

Acamprosate. Acamprosate (Campral™) is given to patients to help them manage
alcohol cravings when a person has given up drinking (Buechler, 2020). The FDA
approved it in 2004, although it has been used in Europe since the 1980s. The exact
mechanism of action acamprosate in reducing alcohol craving is still unclear, but it
contains significant structural homogeneity with GABA receptor and thought to modulate
the glutamate action at the N-methyl-D-aspartate (NMDA) receptor in the human brain. It
has been extensively studied in different doses to assess its real efficacy at a certain dose.
Acamprosate has a dose range of 1332 to 3000 mg/d, usually prescribed as 666 mg three
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times daily. It is noteworthy that acamprosate has no black box warning. It also has no
specification based on gender (Kranzler & Gage, 2008). Acamprosate helps to increase the
duration of abstinence from alcohol. The possibility of getting back to drinking after taking
this drug is very low. It is relatively more effective than any other drug used in the
management of AUD (Garbutt, West, Carey, Lohr, & Crews, 1999; Katie Witkiewitz,
Saville, & Hamreus, 2012). The structure of Acamprosate is given below in Figure 4.

Figure 4. Structure of Acamprosate. One of the most recent drugs approved for the
treatment of AUD. It helps patients with withdrawal symptoms.

Oral naltrexone. FDA approved oral naltrexone in 1994 as an anti-craving agent
for the management of alcohol dependence (Liang & Olsen, 2014). Naltrexone actively
antagonizes μ-opioid receptor (OPRM1) and most possibly work via suppressing the brain
reward systems, which use the neurotransmitter dopamine to communicate. The anticraving action of naltrexone is most profound in patients with specific genetic
polymorphisms in them. A black box warning for oral naltrexone says not to use this in
patients diagnosed with acute hepatitis or hepatic failure. Caution also should be followed
by patients with severe liver or renal insufficiencies, yet no dose adjustment is

25

recommended so far. Patients already using naltrexone should not use opioids at the same
time. Patients are often suggested to carry a card to notify medicine suppliers that they are
administering an opioid receptor blocking agent. The structure of Naltrexone is shown
below in Figure 5.

Figure 5. Structure of Naltrexone. It was first prescribed for the treatment of opioid
addiction.

Other pharmacologic therapies. The existing FDA-approved drugs for AUD are
trashed with several side effects and less effective in many cases, as they do not fully cure
it. Thus investigation and search for new drugs are on the rise (M Edwards, A Kenna, M
Swift, & Leggio, 2011). Topiramate, baclofen, ondansetron, sertraline, nalmefene, and
aripiprazole are currently under investigation. Topiramate is thought to exert its
mechanistic effect as a GABA receptor agonist and glutamate receptor antagonist. Side
effects of this investigated medication include anorexia, paresthesia, and taste perversion.
Baclofen is a GABA-B receptor agonist, according to the published data currently under
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investigation to assess its efficacy (Johnson, 2005). Sertraline is a selective serotonin
reuptake inhibitor used to treat anxiety, sleep disorder, depression, and other psychiatric
disorders. It is now under assessment for its potential efficacy in managing AUD.
Why New Treatments are Needed?
One of the common side effects of one of the FDA-approved drugs, oral naltrexone
(vs. placebo), includes somnolence, nausea, vomiting, reduced appetite, abdominal pain,
insomnia, and dizziness (Roesner et al., 2010). This particular drug blocks the therapeutic
efficacy of opioid analgesics and can precipitate the incidence of opioid withdrawal in a
patient who is already physically dependent on opioids. Additionally, long-acting
naltrexone can bring about the same adverse outcomes as oral naltrexone and injection-site
reactions (Garbutt et al., 2005). Furthermore, naltrexone is quite less effective for
maintaining abstinence from alcohol in most patients with alcohol use disorder (Carmen,
Angeles, Ana, & María, 2004; Srisurapanont & Jarusuraisin, 2005). Naltrexone is also well
known to induce fatigue and anxiety; in addition, it impairs the patient's thinking process
or reactions (Losekam, Kluge, Nittel, Kircher, & Konrad, 2013; Sonne & Brady, 2000;
Sullivan & Nunes, 2005). Another drug for alcohol use disorder, acamprosate, has the most
commonly observed side effects in the clinical trials, including headaches, diarrhea,
flatulence, nausea, etc. (Kiefer & Wiedemann, 2004; Mann, 1996). It is also known that
disulfiram is trashed with peripheral neuropathy's side effects (Filosto et al., 2008).
It is notable that current treatment patterns for AUD, including pharmacological
treatments and available medications, certainly have lower success rates, suggesting a clear
necessity for new potential drugs. Till today, most often, non-pharmacological therapies
are still the first and sometimes only available treatment method for the people suffering
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from AUD. The drugs currently available for treating AUD only deal with the side effects
of quitting the drinking habit. The currently available medications try to suppress or
manage the adverse effects that originate from alcohol use disorders. But it is a matter of
great concern that none of the medications treat the actual addiction due to alcohol use.
The medical and scientific communities' existing knowledge and expertise have certain
gaps in how to treat addiction in a sustainable matter, including alcohol use disorder. One
of the first things that need to be known is where in the brain or in which receptor alcohol
targets. The abuse-related liability of addictive drugs is also needed to be ascertained. It is
now a demand for an effective drug that can be found that can utterly and effectively target
the specific area in the brain or specific receptor protein attributed to the alcohol use
disorder. A sustainable drug that is found to be successful could hugely help people manage
their addiction to alcohol or for those where other treatment options and therapeutic
approaches have not worked.
Research Goal
In this thesis, two different drugs, each of which target separate receptors in the
brain, were tested to determine whether either of these drugs could be effective in the
treatment of alcohol use disorder in mice models. The two interest drugs are L-745,870
and PSNCBAM-1, both of which are described in more detail in the subsequent chapters.
The experimental methods and results for each drug are also described in detail in the
following chapters of this work. Additionally, I describe the optimization of a two-bottle
choice procedure for future use as a model of AUD. Our goal is to find a new drug that
could help people in their addiction grips to have a fighting chance against alcohol
addiction.
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Chapter 2
Materials and Methods
Animals
For all experiments, we used drug naïve male C57BL/6 mice purchased from Charles
River Laboratories (Wilmington, MA). Animals were grouped-housed in the temperature(21-23°C) and humidity-controlled (45-50%) vivarium at Cooper Medical School of
Rowan University under a 12 h light/dark cycle (lights on at 0700, off at 1900). Housing
enrichment is provided by polycarbonate cages with ad libitum food and water. Animals
received enrichment provided by paper Bio-Huts and/or nestles. Testing animals arrive in
vivarium approximately 28 days of age, weighing 23-30 grams, and need to be familiarized
about 7/10 days before testing. During the habituation period, the mice were given free
access to foods and water. The picture of C57BL/6 mice is shown below in figure 6.

Figure 6. Picture of a C57BL/6 drug naïve mouse obtained from Charles River
Laboratories.
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Drugs
PSNCBAM-1 (a negative allosteric modulator of the cannabinoid CB1 receptor) and
L-745,870 (a dopamine D4 receptor) were used in this study to determine if either could
be work in the treatment of alcohol use disorder. The vehicle used for PSNCBAM-1 was a
mixture of 10% dimethyl sulfoxide (DMSO), 10% Tween 80, and 80%saline. DMSO is
commonly used to dissolve drugs (Brayton, 1986). The vehicle for L-745.870 was
physiological saline. PSNCBAM-1 and L-745.870 were purchased from Tocris Bioscience
(Ellisville, Missouri).
Open-Field Locomotor Test
In this experiment, three groups of 20 Male C57/Bl6 mice were used. PSNCBAM1 (0, 10, or 30 mg/kg) was administrated by intraperitoneal (i.p.) injection. The
PSNCBAM-1 vehicle was 10% dimethyl sulfoxide (DMSO), 10% tween 80, and 80%
physiological saline.
Apparatus. Open-field locomotor test apparatus was a 40 × 40 × 35 cm Plexiglas®
open-field, and a camera mounted overhead recorded and tracked locomotion of animals
that was connected to the Any-maze behavioral analysis software of a computer. Two
regions of this field are the center region by 20*20 cm and the rest of the outer regions of
the apparatus.
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Figure 7. Picture of Open Field apparatus. Camera mounted overhead that records the
locomotion of animals

Procedure. To measure animal behaviors, the open field is one of the oldest and
most widely used platforms. This experiment is easy and quick to determine different types
of behavioral information (Seibenhener & Wooten, 2015). An open field test was done to
determine whether locomotor activity was disrupted due to the injection of a drug in mice.
At the beginning of these experiments, mice were placed in an open field chamber for 20
minutes to explore the chamber unchecked. The mice were then taken out, and
intraperitoneal injection of either 3.0 mg/kg L-745,870 or saline were given during the L745,870 study, and either 10 mg/kg PSNCBAM-1, 30 mg/kg PSNCBAM-1 or the vehicle
mixture were given during PSNCBAM-1 study. After that, the mice were placed in the
open field compartment for 40 minutes. There is a camera on top of the open field chamber
that records the movements of mice. After every use, the chamber was cleaned by 70%
isopropyl alcohol to make the apparatus ready for the next mice.
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Statistical analysis. The total distance, time in the center zone, and time in outer
zones were collected for further behavioral analysis. The total distance traveled by animals
was statically analyzed using GraphPad Prism 6.0 statistical analysis software.
Rotarod
The rotarod performance test is a behavioral analysis to test motor coordination and
balance in rodents, especially to test the effects of different drugs and substances.
Additionally, testing rotarod coordination gives the ability to characterize the motor
phenotype of rodents. This study aimed to determine if dopamine D4 antagonist L-745,870
disrupted the mice model's coordination function. Evaluating the period, the mice could
maintain their coordination in an increasing rotarod speed. In the initial study, mice were
placed on a black round rotating rod that gradually increased its speed from 4 RPM to 40
RPM. Before injecting, there were two 10 minutes segments, where 6 minutes of run and
4 minutes resting period and then again 60 minutes of post-injection experiments with the
same procedure as six of ten minutes segments with six minutes run and 4 minutes resting
period. In the first part of the experiment, different concentrations of ethanol (1.2 g/kg,
1.6g/kg, 2.0 g/kg) EtOH were injected.
Rotarod apparatus. The animals were placed apart on a horizontal black rod that
rotates about its long axis. Initial rotation was set at 4 RPM and increased to 40 RPM. and
the mice had to walk forward to remain upright and not fall from the rod (Deacon, 2013).
The mice were either injected with EtOH or L-745,870 to determine whether the dosages
of each altered their coordination activity. A white sensor plate under the rotating rod that
senses the time when mice fall from the rod. This rotarod machine was connected to Med
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PC that indicated the falling time of mice in second and RPM speed in the falling time. We
recorded falling time and speed manually.

Figure 8. Rotarod Apparatus. The center black rod rotates about its long axis. A sensor
white plate under the rotating rod.

Self-Administration Operant Training
Self-administration is the process of a subject (usually animal) administering a certain
pharmacological substance to themselves. Self-administration is a kind of operant
conditioning where the reward is usually a drug. Alcohol operant self-administration
training is a critical tool for studying the neural circuits both in alcohol-seeking and
consummatory behaviors for studying the neural basis of underlying alcohol use disorders.
Ethanol self-administration using operant conditioning procedures has been firmly
established in several species, including monkeys, rats, and mice (Lopez & Becker, 2014).
It was tried to observe whether the two drugs, L-745,870 and PSNCBAM-1, reduced
ethanol's self-administration.
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Operant chamber. Standard operant conditioning chambers were well-ventilated
and sound-attenuated with fans. Every box contained a reward vessel in the center and two
nose poking holes in two sides of the vessel. A house light inside the chamber and a
stimulus light were also available in each response hole. Tube connected with syringes was
put into a plunger pump inside the box that was used to supply either ethanol or food. An
image of the self-administration apparatus was demonstrated below.

Figure 9. Self-Administration Operant Chamber. There are two nose poke holes inside the
chamber, the correct hole being on the left side and incorrect hole being on the right side
and a reward receptacle in the middle of right and left hole.

Self-administration training. This training was primarily for 60 minutes daily, but
the training session increased to 120 minutes daily when mice could nose poke into the
active hole to attain the reward of either diluted vanilla Ensure or ethanol. A fixed-ratio
(FR) system was used for training where a fixed number of correct nose pokes were
required to get a reward. Training ratios started at FR1- for a reward to earn, one correct
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nose poke on the programmed drug side is required. The training ratio was gradually risen
to FR4- four consecutive nose pokes at the correct hole was required to get the reward.
Three correct and consecutive nose pokes and then one incorrect nose poke would require
starting from the beginning again. According to the training, mice that were restricted for
food, nose poked for rewards and for a food reward of Ensure, mice were couched to nose
poke. Dilution of Ensure into a 50% Ensure: 50% water ratio was done gradually by adding
water. Then ethanol replaced the water when the Ensure: water ratio showed a stable
response. When the ethanol concentration came down to 10% w/v, this process was
stopped. Water was added in place of the Ensure to make a mixture of 10% w/v ethanol in
water. The 10% w/v mixture was too high as the number of nose pokes for the alcohol
mixture reduced instead of increasing and hence the mixture was converted to 8% w/v
ethanol in water. The 8% w/v ethanol in water was used in the operant chambers for the
two drugs, L-745,870 and PSNCBAM-1.
Testing of pharmacotherapeutics for self-administration. We used eight mice
which showed best nose poke response for the mixture out of sixteen trained mice. One
day of the week was the testing day with drug and rest of the days were used as training
days. Latin square design was used to arrange the testing session. The two drugs, L-745,870
and PSNCBAM-1 were tested at different sessions and with different sets of mice each
time. In case of L-745,870, the mice were injected with either 1.5 and 3.0 mg/kg L-745,870,
or saline vehicle, respectively. At the time of PSNCBAM-1 testing session, the mice were
injected with either 10 and 30 mg/kg PSNCBAM-1, or the vehicle (10% Tween-80, 10%
DMSO and 80% saline solution). In the second testing session of PSNCBAM-1, an
intermediate dose of 18 mg/kg was also given in the same way.
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Statistical analysis. GraphPad Prism, version 8.3 (San Diego, CA, USA) was used
to analyze the data. All the results are demonstrated as means ± SEM (standard error of the
mean). Pre-planned Bonferroni t-test was used to conduct individual group comparisons,
in case of a significant effect using one-way analysis of variance (ANOVA). Bonferroni ttest is a multiple level comparison tool used extensively in statistical analysis that does not
allow data to incorrectly appear as statistically significant. Presence of any statistically
significant difference between the averages of the unrelated groups were ascertained using
ANOVA as well.
Conditioned Place Preference
The conditioned place preference (CPP) is a standard preclinical behavioral analyzing
model which has been widely used for the research of abuse and addictions for drugs, food,
sex, etc. CPP, has four phases-acquisition, expression, extinction, and reinstatement (Wu,
Yang, & Wang, 2016). The goal of the study was to test the effects of the CB1 negative
allosteric modulator, PSNCBAM-1 and dopamine D4 antagonist to determine if it could
reduce ethanol self-administration behavior in adult male mice.
For this PSNCBAM-1 and L-745,870 related studies, we used modular CPP chambers
from Steeling for using with Any-Maze software. These chambers included two
rectangular shapes compartments, described by the white and black wall which are
connected through one small central compartment which has gray color wall. There is no
specific feature of this center compartment and two doors between two adjacent
compartments connected with this middle compartment that allows animals to move freely.
The compartments are either circular grid or square grid flooring with the similar marked
wall. Two adjacent chambers characterized by the white and black surroundings are
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connected through a small central gray compartment. The two end compartments are either
paired with a drug or vehicle during experimental training. The center compartment is not
paired with either the drug or the vehicle, it is considered neutral space within the entire
compartment. The center compartment allows the mice to move freely between the two
adjacent compartments when the gates to those compartments are raised.

Figure 10. CPP Chamber. The white compartment is located on the left side and black
compartment located on right side. The middle gray compartment on the picture is the
neutral compartment.

Initial preference test. Initial preference test is common for most of the place
preference studies. During the initial preference test, animals can access both chambers to
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show pre-existing preference for any of the two chambers before administration or train
with any drug. The initial preference was measured by allowing the animal to explore in
both compartment for 30 minutes. The amount of time animals spends in the compartment
is recorded by the software. Before conditioning, we calculated the ratio of time animal
spent in an individual chamber. After completion of conditioning, the initial preference
value is used to assess the rewarding effects of drugs and sometime, this value is used to
fix which chamber can be related to drug or vehicle. In unbiased experimental procedure
the drug-paired and vehicle paired compartment were assigned randomly but in a biased
procedure, least preferred compartment is paired with the drug of interest.
Drug conditioning. The standard procedure for place conditioning with drugs is to
pair one distinct chamber with a drug injection for one session, and pair a second chamber
with vehicle in a separate session. Conditioning can be defined as training or acquisition.
During training, animals are repeatedly and alternately exposed to either the investigative
drug while confined to one compartment or vehicle to the other compartment. When the
drug side and the vehicle side were determined for the individual, the mouse was placed to
drug paired chember after injecting with drug and the alternative session, the same mouse
was placed to vehicle paired compartment after injecting with vehicle. Animals were
trained off 10 days of acquisition period to develop place preference. Proper training was
required to start testing the animals. Everyday before start the experiments, animals health
and behavior parameter was observed and noted down. Only healthy animals with proper
percent of weight gain or lose, no injury, no infection, no hyper activity animals were
injected with drug or vehicle in this experiments.
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CPP expression. In this stage, animals were undergo testing to get place preference
score. There is no injection in this CPP expression stage. Mice were allowed to access any
of the compartment in the apparatus.
CPP extinction. After CPP training and expression, the conditioned mice were
repetadely exposed to all CPP apparatus freely in absence of drug or vehicle.This extinction
placed 3 days, for this reason, animales may losse of place preference.
CPP reinstatement. It can be indused by re-exposure to the drug which is known as
drug primed reinstatement. The forced swim and the foot-shock are the two important and
widely used testing methods for stress indused reinstatement. In our study, we used forced
swim technique to induce stress. A 30cm hight and 20cm diameter and build of transparents
plexiglas inescapable cylindrical tank was used where mice were placed. The water
temperature was 25-28C and the water level was 5-20 cm. One mouse was placed inthis
cylinder for force swim for 6 minutes and then was dried and placed in CPPchember for
30 minutes. The anti-stress, anti-addiction, anti-anxiety effect of drugs was tested on this
stressed mice.
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Figure 11. General schematic presentation of CPP procedure adapted from Fernandes,
M.F.A. and S. Fulton, 2016 (Fernandes & Fulton, 2016).

In this CPP study, place preference is explored at various dosages of ethanol (1.2g/kg,
1.6g/kg, 2.0 g/kg). Mice were trained on alternating days with either ethanol or saline
vehicle, with each being paired to a compartment. The 2.0g/kg dose of ethanol was the one
that most optimized the addiction preference and was the dose used in subsequent
experiments involving CPP.
After establishing the effects of ethanol in CPP testing, the therapeutic potential of
novel medications on ethanol abuse, including the CB1 negative allosteric modulator,
PSNCBAM-1, and dopamine D4 antagonist L-745,870 were studied. In the PSNCBAM-1
study, the mice were subjected to pre-injection 10 mg/kg PSNCBAM-1, 30 mg/kg
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PSNCBAM-1, or the vehicle and post-injection of either 2.0 g/kg ethanol or saline and
placed in the CPP apparatus to determine the efficacy of PSNCBAM-1 as a potential antiaddiction drug. In a second PSNCBAM-1 study, an intermediate dose of 18 mg/kg was
tested in the same manner. Again, they were then placed in the CPP apparatus to determine
the efficacy of PSNCBAM-1 as a potential anti-addiction drug. In a second PSNCBAM-1
study, an intermediate dose of 18 mg/kg was tested in the same manner. In the L-745,870
study, the mice were subjected to a pre-injection of either 1.5 mg/kg L-745,870, 3.0 mg/kg
L-745,870, or saline: and a post-injection of either 2.0 g/kg ethanol or saline. They were
then placed in the CPP apparatus to determine the efficacy of L-745,870 as a potential antiaddiction drug.
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Chapter 3
The CB1 Negative Allosteric Modulator PSNCBAM-1 has a General Anhedonic
Effect in Mouse Models of Alcohol Addiction
Abstract
Previous research has determined that substance use disorders could be treated by
attenuating the signaling of the cannabinoid receptor type 1 (CB1). However, the clinically
used CB1 antagonist/inverse agonist rimonabant produced profound adverse effects,
including anhedonia and suicidality. Current CB1 drug development focuses more on CB1
negative allosteric modulators (NAMs) such as, PSNCBAM-1. These NAMs are thought
to be quite promising in the sense that different pathway of action might be provided for
restricting CB1 signaling along with diminished adverse effects. PSNCBAM-1 has never
before been assessed in AUD models. This study evaluated the effects of CB1 NAM
PSNCBAM-1 (10, 18, and 30 mg/kg, i.p.) in adult male mice. PSNCBAM-1 did not
significantly interfere with the locomotor activity. Oral ethanol self-administration was
suppressed by PSNCBAM-1 in a dose-dependent manner, where ethanol rewards were
significantly decreased at 30 mg/kg dose, but not at the 10 or 18 mg/kg doses. Selfadministration of palatable food (diluted vanilla Ensure) was also reduced by 18 and 30
mg/kg PSNCBAM-1. Taken together, these results indicate that PSNCBAM-1 induced a
non-specific anhedonic effect. This may hinder its possible use in AUD treatment.
The Cannabinoid Receptor Type 1 (CB1) as a Target for AUD Treatment
Treatment of various complexities like pain, obesity, addiction, inflammation, etc.
are focused on cannabinoid signaling, making it an important medicinal compound (Ye,
Cao, Wang, & Zhou, 2019). The discovery of Δ9-tetrahydrocannabinol is a landmark
incident in the pharmacological research of cannabinoids, principally known for its effect
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on the brain via cannabinoid receptors(Horswill et al., 2007). The unique endocannabinoid
system in the vertebral CNS and PNS mainly includes the endogenous cannabinoids, its
receptors and the enzymes which are responsible for destroying and synthesizing
endocannabinoids (Mackie, 2008).
Although some evidence exists in favor of the existence of a cannabinoid “CB3”
receptor, the two major subtypes are CB1 and CB2. CB1 and CB2 belong to the
superfamily of G-protein-coupled receptors (Horswill et al., 2007). Subtype CB1 is
primarily expressed in the brain, and found in peripheral tissues, including testis and
adipose tissue. In contrast, the CB2 subtype is unique to the immune cells for immune
response (Horswill et al., 2007). The cannabinoid receptor subtypes, not being
homogenously scattered in the brain, remain densest in territories where cannabinoids exert
effects on cognition, short-term memory preservation, motor function and movement
(Pertwee, 1997). Therefore, many other psychoactive outcomes of cannabinoids are
mediated by these receptors. In addition, CB2 receptor is known for its more specific and
targeted distribution, residing in brain neurons other than its existence in few immune cells
(Mackie, 2008). Beside its presence in the peripheral tissues and immune cells, CB2
receptors are also found to be present in nearly all hematopoietic cells including natural
killer cells, lymphocytes, neutrophils, macrophages, etc. (Kumawat & Kaur, 2019).
Sometimes they are found in kidneys and pancreas as well. Natural psychotropic
reflex in the brain is disrupted in the brain when CB2 receptors are absent. Not only this,
but many other pathophysiological circumstances are also vastly regulated by CB2
receptors. For instance, progression and management of a number of diseases, including
atherosclerosis, cardiovascular abnormalities, diabetes, cancer, etc. are conducted by CB2
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receptors (Kumawat & Kaur, 2019). As CB2 is a highly clinically studied receptor,
evidences suggest that CB2 receptor agonists are capable of effectively suppressing
neuropathic pain and inflammation (Kumawat & Kaur, 2019). Since both receptors are
known to associate with inhibitory G proteins and consequently fall into similar
pharmacological effects, hence, some important events such as, partial agonism, inverse
agonism or functional selectivity have determinant role in the cellular response of certain
cannabinoid receptor ligands (Mackie, 2008).
In recent times, allosteric binding site, that is quite specific from the orthosteric site,
has emerged as an effective alternative mechanism for the management of G-protein
coupled receptors (GPCRs) (German et al., 2014). Essentially, allosteric modulators can
be characterized as ligands which tie up to these sites to modify the receptor signaling
characteristics of the orthosteric ligand, and altering the functional efficacy, potency, and
ligand affinity. Allosteric modulators can be chosen over traditional orthosteric drugs,
firstly because of the fact that subtype selectivity is relatively greater for the allosteric
modulators (German et al., 2014). This higher subtype selectivity is related to the higher
sequence diversity at extracellular allosteric binding sites, in comparison with the
traditional orthosteric domains for specific GPCR subtypes. Secondly, we have greater
selectivity of tissues for allosteric modulators, exerting effects only where endogenous
ligands are present. The third and final reason behind this is, saturable effect of the
allosteric modulators, as they are dependent on endogenous ligands for signaling (German
et al., 2014). Recently, a number of allosteric ligands that are specific for CB1 receptor
have been reported (German et al., 2014). Compound PSNCBAM-1 and Org27569, -
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27759, -29647 are extensively studied among them, though there remains complexity
regarding the pharmacological index of these allosteric modulators (German et al., 2014).
There are two types of allosteric modulators; one is positive allosteric modulators
or PAMs, another is negative allosteric modulators or NAMs (Bertini et al., 2017). This
classification is based on the type of modulation in accordance with the affinity and
efficacy of the orthosteric agonists. A number of compounds are already established as
CB1 receptor allosteric modulators, for example, NAM Org27569 (an indole derivative),
NAM PSNCBAM-1 (a urea derivative), PAMs RTI-37133, and ZCZ01134 (Bertini et al.,
2017). During the year of 2007, high throughput screening of a small library led to
discovery of PSNCBAM-1. The pharmacological index of this compound is quite like
Org27569. In an in vivo study of acute feeding model, PSNCBAM-1 demonstrated reduced
food consumption and body weight in an in-vivo acute feeding model (Bertini et al., 2017).
One of the similar pharmacological attributes of PSNCBAM-1 with Org27569 is
both of the allosteric modulators enhance [3H]CP55,490 binding levels, which is positive
allosteric modulation, but inhibit agonist-mediated responses in functional assays, which
is negative allosteric modulation (Nguyen et al., 2018). The positive allosteric modulatorantagonists (PAM-antagonists) systematically enhance the agonist affinity for the receptor
but at the same time reduce the co-bound agonist functional efficacy (Nguyen et al., 2018).
Some other reasons for which researchers prefer to target allosteric binding sites
include spatiotemporal control, specificity of mechanistic pathways, selectivity of
subtypes, and more importantly a ceiling effect is attainable which helps to manage the risk
of overdosing (Dopart, Immadi, Lu, & Kendall, 2020). The characteristic property of
PSNCBAM-1 demonstrated that it promotes an active CB1 conformation, where it actively
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assists the binding of CB1 agonist CP55,940, at the same time suppressing the inverse
agonist SR141716A binding. However, it was observed that PSNCBAM-1 showed
noncompetitive, inhibitory outcomes in GTPγ S and cAMP assays (Dopart et al., 2020).
Inhibition of the Cannabinoid Receptor Type 1 (CB1)
Rimonabant (SR141716) is amongst one of the prominent CB1 receptor antagonists
or inverse agonists which was formerly accepted in Europe for the management of obesity
(Nguyen et al., 2018). In addition to this, significant clinical benefits were observed via
using CB1 receptor antagonists in abrogating drug seeking tendency in animals and ceasing
the craving for smoking (Nguyen et al., 2018). Based on these outcomes, it can be
rationalized that CB1 antagonism may pave the way for the treatment of drug addiction.
Rinaldi-Carmona first synthesized Rimonabant and is the very first selective, potent, and
orally active antagonist of the cannabinoid receptor (Soyka et al., 2008). It is evident from
in vitro and in vivo assays that rimonabant demonstrates antagonistic property in
behavioral and pharmacological aspects mediated through cannabinoid receptor agonists
and as a result reduces voluntary alcohol intake in animal studies (Soyka et al., 2008).
Along with Europe, the drug has already been approved in The Africa and Middle
East for the management of obesity (Soyka et al., 2008). As far as the role of rimonabant
in the treatment of addiction is concerned, it dose-dependently decreased alcohol
consumption in the alcohol-preferring rodents (Soyka et al., 2008). It is observed in clinical
study, rimonabant pretreatment abrogated the up rise of alcohol intake after CB1 agonist
treatment. Of late, it was found that rimonabant significantly decreased reward-related
responses in animal studies. But rimonabant has not attained approval in the US till date
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(Soyka et al., 2008). Safety profiling and side effects evaluation is very important
for any prospective drug like compound. So far, quite a few studies have been conducted
on the safety and side effects of rimonabant where depression and anxiety are found to be
the most common side effects (Després, Golay, & Sjöström, 2005). In some other studies
there were presence of cases like visible irritability, stress, insomnia, and sudden panic
attacks (Buechler, 2020). A meta-analysis was run by Christensen et al. on four of the
Rimonabant in obesity Studies, which revealed that patients who took 20 mg dose of
rimonabant, have shown to cease the treatment 2.5 to 3.0 times more as symptoms of
anxiety and depression persisted (Buechler, 2020).
Due to presence of abundantly devastating side effects, rimonabant was
immediately withdrawn from the market. Thus, allosteric modulators are in need of an
alternative that can target the CB1 receptor signaling pathway for therapeutic outcome.
That’s where PSNCBAM-1 came into prominence which is one of the earliest CB1
receptor allosteric modulators (Nguyen et al., 2018). The IUPAC name for PSNCBAM-1
is 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1- yl) pyridin-2-yl) phenyl) urea. The chemical
structure of PSNCBAM-1 is given below in figure 12.

Figure 12. Structure of PSNCBAM-1, the cannabinoid type 1 negative allosteric modulator
was obtained from Sigma Aldrich in the US.
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Results
Open-field locomotor test. Ascertaining the safety profile of any drug is very
important before commencement of further clinical studies. Initial control studies were
conducted for PSNCBAM-1 to observe whether the drug reduced any locomotor function
in mice. The initial control studies were performed in the open field method. To allow the
mice to experience the open field chamber unhindered, experimental mice were put into
the open field chamber for a period of initial 20 minutes. Following initial 20 minutes, each
mouse received an i.p. injection of either 10 or 30 mg/kg PSNCBAM-1, or the vehicle
mixture and then put into the open field chamber for another 40 min period. The mice
behavior being recorded using a camera, both doses of 10 and 30 mg/kg PSNCBAM-1, i.p.
did not significantly suppress the locomotor activity (Figure 13).

Figure 13. Neither of the doses of 10, 18 or 30 mg/kg PSNCBAM-1 significantly impacted
locomotor activity in the open field method test. Male mice were put in the open field
chamber for initial 20 minutes, behavior was recorded and then they were treated with i.p.
injections of vehicle (n = 16), 10 mg/kg PSNCBAM-1 (n = 8), or 30 mg/kg PSNCBAM-1
(n = 8), finally, behavior was recorded for additional 40 minutes. (A) 20 minutes after
introduction into the open field chamber, mice were injected 10 or 30 mg/kg PSNCBAM1 or vehicle alone and locomotor activity was assessed for additional 40 minutes. (B)
Overall post-injection distance traveled by mice was not found significantly different
throughout the experiment. Data is demonstrated as means ± SEM of distance traveled by
mice in 5-minute bins.
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Conditioned place preference. Prior to standard side training, conditioned place
preference (CPP) training was modified for 2.0 g/kg ethanol to provide a PSNCBAM-1 or
vehicle mixture pretreatment. As a pretreatment to 2.0 g/kg ethanol or saline vehicle dose,
varieties of doses like 10, 18, and 30 mg/kg and a vehicle mixture as i.p. injections were
assessed, where the PSNCBAM-1 pretreatment did not affect the rewarding value of
ethanol (Figure 14). Statistical one-way ANOVA analysis did not show any significant
effect of PSNCBAM-1 pretreatment (F (2,26) = 0.3469, p > 0.7).

Figure 14. CPP training was modified to include PSNCBAM-1 or vehicle pretreatment
prior to 2.0 g/kg ethanol. PSNCBAM-1 did not significantly decrease place preference for
2.0 g/kg ethanol. Vehicle pretreatment (n = 9) was not significantly different from 18
mg/kg (n = 10) or 30 mg/kg (n = 10) PSNCBAM-1 pretreatment and did not affect
acquisition of ethanol conditioned place preference. All results are presented as means ±
SEM.
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Ethanol self-administration. To satisfy one of the main objectives of this study,
the effects of PSNCBAM-1 on ethanol self-administration were measured. Mice were
trained to self-administer 8% w/v ethanol in water10, 18, and 30mg/kg PSNCBAM-1 and
vehicle (10% DMSO, 10% Tween 80, and 80% saline) were tested using a Latin square
design. Mice were injected PSNCBAM-1 or vehicle i.p. immediately prior to a two-hour
ethanol self-administration session. PSNCBAM-1 exhibited dose-dependent attenuation of
ethanol self-administration via decreasing ethanol rewards at 30 mg/kg dose (Figure 15).

Figure 15. Pretreatment with PSNCBAM-1 significantly decreased oral ethanol selfadministration. 8% w/v ethanol in water was modified to provide PSNCBAM-1 or vehicle
pretreatment in the self-administration training just before the standard side training.
Pretreatment with 30 mg/kg (n = 8) PSNCBAM-1 significantly attenuated oral ethanol selfadministration, but 10 and 18 mg/kg (n = 8) doses of PSNCBAM-1 did not. All results are
presented as means ± SEM; * p < 0.05 in comparison with vehicle pre-treatment.
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Palatable food self-administration. Mice were trained to self-administer a mixture
of 50% Ensure: 50% water for the food self-administration and a Latin square design was
used to test two doses, 10 and 30 mg/kg of PSNCBAM-1 and vehicle (10% DMSO, 10%
Tween 80 and 80% saline). An intermediate dose of 18 mg/kg PSNCBAM-1 was given in
the second round of testing. On test days, i.p. injections of PSNCBAM-1 or vehicle were
given just before a 2-hour self-administration session. The test revealed that palatable food
self-administration was dose-dependently attenuated by PSNCBAM-1 by decreasing food
rewards at 18 and 30 mg/kg doses. Statistical one-way ANOVA analysis showed a
significant effect of PSNCBAM-1 treatment (F (3,18) = 4.264, p = 0.0193), where the preplanned Bonferroni tests showed a significant difference between vehicle and 30 mg/kg
PSNCBAM-1 treatment (t = 3.016, p < 0.05).

Figure 16. Pretreatment with PSNCBAM-1 significantly decreased palatable food selfadministration. 50% Ensure:50% water was modified for self-administration training to
provide PSNCBAM-1 or vehicle pretreatment just before standard side training. Doses of
18 and 30 mg/kg (n = 8) PSNCBAM-1 significantly attenuated palatable food selfadministration, but the dose of 10 mg/kg did not. All results are presented as means ± SEM;
* p < 0.05 in comparison with vehicle pre-treatment. ** p < 0.01 in comparison with vehicle
pre-treatment.
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Discussion
In open field tests, PSNCBAM-1 did not significantly affect locomotor activity.
This was conducted to determine PSNCBAM-1 doses tested did not produce general
behavioral disruption or did not significantly disrupt locomotor activity in the open field
initial study. PSNCBAM-1 pretreatment did not significantly influence the acquisition of
place preference to 2.0 g/kg ethanol, suggesting that it did not cause motivational changes
for alcohol as it did not suppress the preference behavior induced by ethanol. PSNCBAM1 also dose-dependently reduced both palatable food and ethanol self-administration.
These results suggest that PSNCBAM-1 produces a non-specific anhedonic effect that
inhibits both food and ethanol self-administration. Prior to these experiments, most studies
involved in investigating the drug PSNCBAM-1 have attempted mainly to determine its
effect on obesity-related disorders (Dopart et al., 2020). A study investigating the
hypophagic effects of PSNCBAM-1 in rats concluded that, in an acute rat feeding model,
PSNCBAM-1 significantly reduced food intake as well as body weight (Horswill et al.,
2007). Another study done by Wong Kai in a lab out of Oxford University, studied the
specific hypophagic effect of PSNCBAM-1 on rats. (Horswill et al., 2007). One study
reported that PSNCBAM-1 has abolished the reinstatement of extinguished cocaineseeking behavior in rats (Nguyen et al., 2017).
Though the effects of PSNCBAM-1 on obesity are well documented, studies on
addiction are not well mentioned yet, precluding its potential use in AUD or other
neuropsychiatric disorders. It is a demand of analytical understanding that why in our
laboratory tests PSNCBAM-1 exerted an anhedonic effect both for food and ethanol. With
respect to our results and other reports, PSNCBAM-1 could exert this non-specific
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anhedonic effect in most conditions, excluding the issue of what condition or disorder is
being assessed here. To justify whether this is true or not, more research work needs to be
conducted on this drug in other areas as well. The side effect of reduced food intake of the
drug PSNCBAM-1 can be contrasted against the potential success of being a drug for the
treatment of a substance use disorder. If PSNCBAM-1 is found successful as a potential
treatment option for another disease or disorder, it needs to be ensured that both patient
and medical professional are quite aware of the consequence of appetite suppression
exerted by this drug. Yet there are a high number of medications with the side effect of
appetite loss and not limited to high strength medications and attention deficient
hyperactivity disorders (ADHD) (Bristow et al., 1997). There are several important
limitations of this study. The sex of experimental animal can influence the test results; we
only used C57BL/6 male mice and conducted all of our tests only in the light cycle. A study
performed by Dudek and co-workers stated that female mice have greater sensitivity to the
locomotor-activating action of ethanol than males (Dudek, Phillips, & Hahn, 1991). Other
studies indicate that female mice have higher consumption rate of ethanol than males
(Schramm-Sapyta et al., 2014). Though some reports have denied the effect of sex among
adult rats on ethanol consumption. (van Haaren & Anderson, 1994). Additionally, oral selfadministration of alcohol can result in different blood alcohol concentrations based on each
animal’s size, tolerance, and alcohol consumption from the receptacle that was given after
successful nose poking.
Conclusion
In this study, the effect of PSNCBAM-1 in AUD using mice model is assessed. It
was found that locomotor activity was not significantly suppressed by PSNCBAM-1.
53

PSNCBAM-1 pretreatment did not significantly influence the rewarding value of 2.0 g/kg
ethanol in the condition place preference experiment. Ethanol self-administration was dose
dependently attenuated by PSNCBAM-1 in ethanol self-administration experiment,
decreasing ethanol rewards at only 30 mg/kg dose. Palatable food self-administration was
dose-dependently attenuated by PSNCBAM-1 in the food self-administration experiments,
decreasing food rewards at 18 and 30 mg/kg doses. More research in this arena, particularly
on alcohol addiction, cannabinoid receptors, and their role and mechanism in addiction will
provide deeper insight in discovering better treatment strategy for AUD.
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Chapter 4
The Dopamine D4 Antagonist L-745,870 Does Not Affect Locomotor Activity in
Adult Male Mice Model of Alcohol Addiction
Abstract
The dopamine D4 receptor (D4R) receptor has been the center of profound interest
in the study of several addictions, i.e., cocaine addiction and a popular target in the
development of drugs for psychostimulant addiction but has not been tested for AUDs till
today. During this study, the effects of L-745,870, a D4R antagonist were assessed for
AUD in rodent models, using adult male mice. L-745,870 was investigated for initial
control studies with 1.5 and 3.0 mg/kg, i.p. doses which was found to exert no significant
disruption on locomotor activity. Tests were conducted with diluted vanilla Ensure and
ethanol, where it was found that palatable food and ethanol self-administration (8% w/v
ethanol in water) was not significantly attenuated as well. Conditioned place preference
training was conducted using a three-compartment chambered conditioned place
preference apparatus with L-745,870 pretreatment that did not hamper the rewarding value
of 2.0 g/kg ethanol. Taken together, all these results signify that D4R antagonism does not
significantly alter the rewarding value of ethanol.
The Dopamine D4 Receptor: an AUD Target?
Considerable amount of interest has been given to the dopaminergic system because
of its pivotal role in regulating the central nervous system (CNS), motor functions,
cognition, reward and endocrine action (Oak, Oldenhof, & Van Tol, 2000). Dopamine
receptors are categorized within the G protein-coupled receptors super-family and is
involved in mediating diseases like Parkinson’s and addiction. These receptors are the
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focus when it comes to studying antipsychotic medications in treating schizophrenia. Five
distinct dopamine receptor subtypes are found in mammalian species in molecular cloning
studies (Oak et al., 2000).
Depending on their amino-acid sequence homology and adenylyl cyclase activity
modulation, dopamine receptors are broadly divided into two groups: D1-like (D1 and D5)
and D2-like (D2, D3, and D4) (Siegel, Miller, & Jemal, 2020). The capacity of dopamine
binding at the time of evolution of biogenic amine receptors have helped to lay down the
origin of these subfamilies (Di Ciano, Grandy, & Le Foll, 2014). Specific downstream
signaling pathways are activated when the D1- and D2-like subfamilies are attached with
different G proteins, such as DRD1 and DRD5 are present in postsynaptic sites of
dopamine-receptive neurons (Di Ciano et al., 2014). Reward and movement regulation
pathways in the brain are highly regulated by dopamine and it is produced in the ventral
tegmental area and in nerve cell bodies via the reward pathway (Juárez Olguín, Calderon
Guzman, Hernandez Garcia, & Barragán Mejía, 2016). Dopamine D4 receptor has
structural and pharmacological similarity with dopamine D2 receptor which gave it
considerable level of attention in the management of psychiatric disorders (Patel et al.,
1997).
L-745,870
The IUPAC name of L-745,870 is 3-([4-(4-chlorophenyl) piperazin1-yl] methyl)1H-pyrrolo [2, 3-b] pyridine. L-745,870 (Tocris Bioscience, Ellisville, Missouri, US) is
evaluated in this study which is a high-affinity, selective dopamine D4 receptor antagonist
via using rodent behavioral models to predict its antipsychotic nature and probable sideeffects in humans (Bristow et al., 1997). Six years after the discovery of dopamine D4
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receptor, the selective and CNS-penetrant dopamine D4 antagonist, L-745,870, was
discovered by researchers from Merck. Preclinical and clinical efficacy studies on L745,870 were published in 1997 (Patel et al., 1997).
Different studies have been conducted using this particular drug, L-745,870. A
group of researchers reported that rats were trained to discriminate amphetamine from
saline and L-745,870 partially abolished the discriminative stimulus effect. (MaronaLewicka & Nichols, 2011). Another study demonstrated that alcohol-dependent male rats
have reduced ability to full-fill a number of emotional-learning tasks during their
abstinence period, but after applying the dopamine replacement agent, levodopa rats
recovered rapidly.(Chouhan et al., 2020). L-745,870 was found to have no beneficial effect
on nicotine self-administration according to another report, however, it did suppress both
cue- and nicotine-induced reinstatement of nicotine-seeking behavior in rats. (Yan et al.,
2012). Additionally, although there are a number of evidences which signify that a selective
D4 receptor antagonist might be a fruitful antipsychotic agent with a lower tendency to
facilitate extrapyramidal side-effects, L-745,870 was found ineffective as an antipsychotic
agent in humans. (Bristow et al., 1997). L-745,870 has also been studied as a possible
treatment option for schizophrenia with a view to ensuring an aim that it would not show
the extrapyramidal side effects that are often seen when using classical antipsychotic
agents. (Zhang et al., 2000).
L-745,870 was formerly studied in our lab and was found to attenuate cocaine CPP.
Based on previously study derived outcome on alcohol and other substance addiction, it
can be hypothesized that L-745,870 will decrease alcohol seeking behavior and overall
alcohol consumption in adult male mice. With a view to justifying this hypothesis, we
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assessed L745,870 effects in ethanol CPP and self-administration studies and this drug was
never assessed in alcohol addiction models.

Figure 17. The Chemical Structure of L-745,870, a dopamine D4 receptor antagonist.

Results
Initial control studies. Initial control studies were conducted to ascertain the safety
parameters for L-745,870 to observe any considerable change in locomotor activity using
open field-testing method and coordination function using rotarod testing method in mice.
To allow the mice to experience the open field chamber unhindered, experimental mice
were put into the open field chamber for a period of initial 20 minutes. Following initial 20
minutes, each mouse received an i.p. injection of either 3.0 mg/kg L-745,870 or saline
vehicle. Mice were taken into the open field chamber for the next 40 minutes to record the
behaviors of the mice using a camera attached with the open field chamber. 3.0 mg/kg, i.p
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dose of L-745,870 suggested that, mice locomotor activity was not significantly disrupted
during the open field initial control study. No mentionable effect of the treatment was found
after an unpaired t-test of total post-injection locomotor activity (t (20) = 0.073, p > 0.9).

Figure 18. Mice locomotor activity was not significantly affected with 3 mg/kg dose of L745,870 in the open field test using male mice. Open field apparatus was used to assess
behavioral aspects for initial 20 minutes. Mice were treated with i.p. injections of saline or
3 mg/kg L-745,870 (n = 11) followed by recording of mice behavior for next 40 minutes.
(A) after remaining for 20 minutes into the open field, mice were given 3 mg/kg L-745,870
or vehicle dose, followed by recording of locomotor activity for the next 40 minutes. All
data are presented as means ± SEM of distance traveled by mice in 5-minute bins. (B) Postinjection distance traveled by mice does not vary much across the treatment. All data are
presented as means ± SEM of total distance traveled by mice in the 40 minutes.

To conduct rotarod study, mice were put onto the black rotating rod where the rod
speed went up from 4 rpm to 40 rpm. Limited five minutes was allocated to conduct this
test or until the mice fell from the rod–whichever first occurred. Testing was carried out
for 20 minutes prior to an i.p. injection of either 3.0 mg/kg L-745,870 or saline vehicle
solution and for 60 minutes after introducing injection. Testing was conducted in ten-
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minute increments. Coordination function of mice in the rotarod study was not significantly
disrupted in the initial control study using 3.0 mg/kg, i.p. dose of L-745,870.

Figure 19. Coordination function is not significantly influenced after providing 3 mg/kg
does of L-745,870 in a rotarod test using male mice. At 10-minute increments, mice were
put onto a rotarod apparatus for 20 minutes in total and the speed and time at which mice
fell down from the apparatus was carefully recorded. Then i.p. injections were introduced
for injecting saline vehicle or 3 mg/kg L-745,870 (n = 11) and time and speed recording
was continued for rest of the 60 minutes at 10-minute increments. All data are presented as
means ± SEM of time spent and at what speed the mice fell down from the rotarod
apparatus in 10-minute bins.

Conditioned place preference. Prior to standard side training, CPP was modified
for 2.0 g/kg ethanol to provide a L-745,870 or saline vehicle pretreatment. After that, two
different doses, 1.5 and 3.0 mg/kg along with a saline vehicle dose of i.p. injections were
given as a pretreatment prior to giving a 2.0 g/kg dose of ethanol or saline vehicle solution.
Our test result demonstrated that rewarding value of 2.0 g/kg ethanol is not significantly
affected (Figure 20). Statistical one-way ANOVA analysis for the ethanol-paired
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compartment of conditioned place preference demonstrated no significant effect of L745,870 treatment (F (2,51) = 2.28, p = 0.11).

Figure 20. L-745,870 pretreatment did not significantly decrease the CPP for the dose of
2.0 g/kg ethanol which was modified prior to standard side training to include L-745,870
or vehicle pretreatment. Neither of the doses, 1.5 mg/kg (n = 13) or 3.0 mg/kg (n = 16) L745,870 significantly suppressed ethanol CPP when it is compared to vehicle (n = 25). All
results are presented as means ± SEM.

Food and ethanol self-administration. To satisfy one of the main objectives of this
study, which is determining ethanol self-administration behavior of L-745,870, two tests
were performed using the self-administration operant chamber that included food and
ethanol self-administration. In case of ethanol self-administration, the trained mice selfadministered 8% w/v ethanol in water and then tested with two doses of 1.5 and 3.0 mg/kg
of L-745,870 along with saline vehicle in a Latin square design. Mice were injected L745,870 or vehicle i.p. prior to two-hour self-administration session on each test day. L745,870 did not exhibit dose-dependent attenuation of ethanol self-administration at either
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dose that were tested. Statistical one-way ANOVA analysis demonstrated no significant
effect of L-745,870 treatment (F (2,14) = 0.42, p > 0.66).

Figure 21. Pretreatment with L-745,870 does not significantly decrease oral ethanol selfadministration. 8% w/v ethanol in water was modified to provide L-745,870 or vehicle
pretreatment in the self-administration training just before the standard side training.
Pretreatment with neither of the doses, 1.5 or 3.0 mg/kg (n = 8) L-745,870 significantly
attenuated oral ethanol self-administration. All results are presented as means ± SEM.

Mice were trained to self-administer a mixture of 50% Ensure: 50% water for the
food self-administration and a Latin square design was used to test two doses via i.p.
injection, 1.5 mg/kg and 3.0 mg/kg of the L-745,870 and along with the saline vehicle
solution. On test days, i.p. injections of L-745,870 or vehicle were given just before a 2hour self-administration session. The test revealed that palatable food self-administration
was not significantly attenuated by L-745,870 at either of the doses tested (Figure 22).
Statistical one-way ANOVA analysis showed no significant effect of L-745,870 treatment
(F (2,14) = 0.37, p > 0.69).
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Figure 22. Pretreatment with L-745,870 does not significantly decrease palatable food selfadministration. 50% Ensure:50% water was modified for self-administration training to
provide L-745,870 or vehicle pretreatment just before standard side training. Neither of the
doses, 1.5 or 3.0 mg/kg (n = 8), L-745,870 pretreatment significantly attenuated palatable
food self-administration. All results are presented as means ± SEM.

Discussion
L-745,870 was found promising in initial studies since the locomotor activity was
not greatly affected in the open field tests or coordination function in the rotarod tests. L745,870 with 3.0 mg/kg i.p. dose did not significantly hamper the locomotor activity in the
open field initial control study and with the same dose it also did not significantly hamper
the coordination function in the rotarod initial control study.
According to our current study, L-745,870 did not work as we expected in
conditioned place preference and self-administration tests. L-745,870 did not significantly
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influence the acquisition of place preference with 2.0 g/kg dose of ethanol at the time of
conditioned place preference side-training, suggesting that L745,870 could not mediate
motivational changes towards alcohol or abolish ethanol induced preference behavior. L745,870 has been previously assessed in our laboratory settings were changed cocaine
mediated behavior in mice. Comparing our experimental outcome for pretreatment of L745,870 (3 mg/kg) and post-treatment of cocaine with the previously studied experimental
outcome of pretreatment of saline with post-treatment of cocaine, L-745,870 was found to
have less preference than cocaine. L-745,870 did not affect both palatable food and ethanol
self-administration which helped us to conclude that L-745,870 does not influence the
rewarding value of palatable food or ethanol, hence effectivity of this drug is questioned to
manage ethanol self-administration behavior or AUD.
Till date, L-745,870 has been assessed in various studies where it is extensively searched
for cure against various diseases. Among them, some studies are focused on alcohol selfadministration study. Dr. Bernard Le Foll's lab recently worked on this drug where they
tested the effect of this drug on operant alcohol self-administration and reinstatement
(Siegel et al., 2020). The study added that dopamine D4 antagonists decrease ethanol
consumption and stress-induced reinstatement at highest dose. The doses of L-745,870
that Le Foll's lab tested (0.5-10 mg/kg L-745,870) were at a broader range compared to
the doses used in our study (1.5-3.0 mg/kg).
No scientific study is free of shortcomings. We only used male mice in our tests,
though it is established that there are significant variations in mice behavior and response
to drugs that is closely linked to sex. Dudek and co-workers demonstrated in one of their
biochemical evaluation of locomotor activity that female mice were relatively more
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sensitive to the locomotor activating effect of ethanol than male mice (Dudek et al., 1991).
It is evident from most scientific studies that ethanol intake is higher in female mice than
in male mice (Schramm-Sapyta et al., 2014). Though some reports have denied the effect
of sex among adult rats on ethanol consumption. To become a potentially promising drug
for other substance use disorder, new methods are demanded to be developed to save time
and resources. Considering the promising effect of cocaine, the effectivity of L-745,870
for becoming a treatment option would depend on the abuse liability of the addictive drug.
It was always under profound focus that the dopamine D4 receptors have a pivotal role in
various substance use disorders. But it needs to be further investigated that whether this
receptor has that much role as it is thought to have. Additionally, search needs to be
conducted to investigate, if there are other receptors like the dopamine D4 that might have
a bigger role in the management of addictions.
Conclusion
We performed several experiments for L-745,870, a D4 antagonist, to assess its
effectivity in the management of AUD. Initial control study consisting of open field and
rotarod testing, L-745,870 did not significantly hamper the locomotor or coordination
function. Pretreatment with L-745,870 demonstrated that it would not affect the rewarding
value ethanol with a dose of 2.0 g/kg in the CPP experiment. L-745,870 also did not
significantly attenuate the ethanol and palatable food self-administration behavior and at
any of the doses tested in the ethanol and palatable food self-administration experiments,
respectively. The analysis that we presented here regarding our experimental results may
not provide the proper and broader insight about the exact mechanistic function of
addiction in the brain. With much more cutting-edge research on other substance use
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disorders including AUD will put us many more steps ahead, as far as research on substance
abuse is concerned. Focus also needs to be drawn into the dopamine D4 receptor and its
mechanistic involvement in addiction and addictive behaviors, which may bring more
knowledge and a wider understanding about the treatment of AUD and other disorders
related to substance abuse.
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Chapter 5
Two-Bottle Choice Preference Test

Concerns about alcohol use disorder (AUD) have risen along with the increased
incidence of patients with diagnosable AUDs. Currently, more than 15 million people in
the United States have a diagnosable AUD annually and nearly one-third of the US adult
population will have a diagnosable AUD at some point in their life. This disorder persists
in humans because of chronic dependence on alcohol (Association, 2000). The U.S.
Department of Health and Human Services characterizes AUD as a medical diagnosis
characterized as a chronic relapsing brain disease with uncontrollable alcohol use, and loss
of self-regulation over alcohol consumption. Alcohol abuse facilitates approximately
88,000 deaths per year in the United States (K Witkiewitz et al., 2019) and costs nearly
$249 billion to the US each year (K Witkiewitz et al., 2019).
Non-pharmacological treatment options are a preferred treatment method for AUD
patients. The U.S. Food and Drug Administration (FDA) has approved four medications to
treat AUDs, disulfiram, acamprosate, oral naltrexone, and injectable long-acting
naltrexone, that can be paired with non-pharmacological treatments. These current
treatments have low success rates, indicating a need for new potential drugs. In order to
identify new candidate medications for AUD, we have developed and used a number of
different behavioral pharmacology techniques. In this experiment, we sought to optimize
the two-bottle choice behavioral paradigm as an experimental protocol to evaluate the
effects of different medications on the preference of mice to consume ethanol over water.
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Background
The two-bottle choice alcohol preference test is a well-known and widely used
experimental technique used in AUD research. In this experimental model, animals are
provided with two bottles, one with a diluted ethanol solution and another with water or
other control liquid. The effect of morphine in lower doses on alcohol and sucrose selfselection was assessed by Ronald R Ulm’s lab (Stromberg, Meister, Volpicelli, & Ulm,
1997). It was observed that, when rats were provided to chooses between sucrose
sweetened ethanol and plain water, significant preference was observed for the sweetened
ethanol. However, when rats were given to choose between sweetened ethanol and
sweetened water, they showed preference for sweetened water, suggesting that the
morphine treatment in lower doses enhanced the sweetened alcohol consumption that was
induced by the reinforcing capacity of sucrose, but not ethanol (Stromberg et al., 1997).
The lab of Rosana Camarini demonstrated using a two-bottle choice model that, ethanol
pre-exposure may enhance ethanol intake in both adolescent and adult mice (CarraraNascimento, Hoffmann, Contó, Marcourakis, & Camarini, 2017). In another study, rats
being experimented in three-day long operant self-administration of 10% sucrose + 10%
ethanol where sucrose was found to be completely faded out (Carrillo et al., 2008). The
ethanol self-administration was established by ethanol intake, pre- and post-procedure 2bottle choice preference tests, and extinction trials. It was observed form this study that,
mean ethanol intake was 2.2 times greater on day 2 when compared with day 1 on the 10%
sucrose + 10% ethanol solution (Carrillo et al., 2008). When the sucrose faded out, the
daily consumption of 10% ethanol over 5 days was observed stable where ethanol
preference was nearly 3-times greater.
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We sought to establish this experimental protocol as an effective tool in order to assess
alcohol preference behavior in our lab, with a view to being able to test animal liquid
consumption preferences, addiction-like behaviors, anhedonia, and depression-like
responses. We monitored consumption of liquids from each bottle over 24 hours for several
months to establish how mice preferred to intake various ethanol- and sucrose-containing
aqueous solutions. Progress on this experiment was halted due to the outbreak COVID-19
pandemic and while we were unable to complete our experiment, though we were able to
evaluate several experimental design parameters.
Methods
Animals. In the first portion of the experiment, we used eight adult C57 male mice
weighing 23-31 g/mice. Upon arrival to the laboratory, the mice were given free access to
food and water during one-week habituation period in a room that was maintained at a
constant temperature of 21-23°C and humidity of 45-50% on a 12h light-dark cycle. Mice
were singly housed to better monitor liquid consumption and handled daily throughout the
experiment.
Solution components. In this study, we used ethanol, sucrose, and regular tap water
to assess the consumption preference behaviors of mice. 95% ethanol (VWR) was diluted
as noted in each experimental condition. Sucrose (Fischer Science) was weighed and added
to solutions as noted in each experimental condition.
General Procedure
At the beginning of the two-bottle choice experiment, all mice were single-housed
and provided with two separate plastic conical graduated bottles with rubber stoppers
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containing a metal dispenser; experimental liquid was released via pressure provided by
mice licking the dispenser. Each bottle contained 10-15 ml of solutions that varied with
changing experimental conditions. Each bottle was replenished daily, and consumption of
each liquid was assessed every day between 10 am to 12 pm. The position of each bottle
was stable in some treatment conditions and in other conditions was changed at regular
intervals to evaluate or eliminate any potential positional preference. Experimental data
was collected by gross eye observation and weighing the bottles, recording the liquid
volume and mass consumed from each bottle. Procedure used here is adapted from Carrillo,
J., et al., 2008, Holgate, J.Y., et al. 2017 and Grim, T.W., et al., 2018 (Carrillo et al., 2008;
Grim et al., 2018; Holgate, Garcia, Chatterjee, & Bartlett, 2017)
Two-Bottle Choice Experimental Conditions
In this experiment, we attempted to identify important variables that might affect the
preference behavior of mice between alcohol and water. We used 8 cages of mice in total
and recorded daily alcohol and water consumption over several different conditions.
Condition 1. We started our experiment with 2% ethanol (w/v) in one tube and
regular tap water in the other tube. Our plan was to gradually increase the concentration of
ethanol to 8%. But we observed that mice drank almost no liquid from either tube. In fact,
they were losing weight because of dehydration. From our observations, the mice were not
used to this type of bottle which might be the reason they avoided drinking any liquid.
Based on this observation, we decided to change our experimental plan and gave them a
sucrose solution to make them drink from the bottles.
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Condition 2. Then we started giving the mice only 10% (w/v) sucrose in water in
both tubes for more than one month. Bottles were filled daily with up to 10 ml of solution
and consumption data were collected. The cages of mice were placed in a regular water
rack to give full access to water to keep the mice hydrated. After two hours of regular water
access time, the mice were placed in a separate rack with no water access other than the
two bottles which were filled with the sucrose solution. In Condition 2, we witnessed the
mice developed a consumption preference for one tube over the other based on its location.
In Condition 3, we swapped the tubes and determined whether the preference for one side
persisted.
Condition 3. After substantial sucrose habituation, we replaced one tube with a 2%
ethanol while the other tube remained 10% sucrose for one week. The ethanol tube was
placed on the side that held the drinking preference seen in Conditions 2 and 3.
Condition 4. Following the mixed results in Conditions 1-4, we altered our training
procedure using a new set of mice who had never experienced the standard housing
conditions that included one large water bottle. Over two weeks, the new set of mice
received 2% EtOH and 10% sucrose together in one tube and water in the other tube. The
position of the tubes was interchanged every other day to reduce any potential positional
preference. The mice were placed into the rack where there was no water access for two
hours other than the tubes in the cage. The data were collected daily and recorded into an
excel sheet. This group of mice demonstrated a promising drinking pattern by preferring
to drink EtOH and sucrose solution than water.
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Results
Condition 1. In the first portion of the experiment, mice did not show any significant
EtOH preference. We started our experiment with 2% ethanol on one tube and regular tap
water on the other tube. We found almost no drinking of any liquid from the tube, and the
mice were losing their weight because of dehydration.

Figure 23. Eight C57 male mice were given 2% w/v ethanol in one tube and water in
another tube. The graph showed that water consumption is relatively higher than 2% w/v
EtOH. The mice do not have preference for 2% EtOH over water.

Condition 2. Then we changed our working protocol where we gave them 10%
sucrose water on both tubes to make them comfortable with drinking from those specialized
tubes for the next four weeks. During this time, they started to drink sucrose water, but the
amount was not significant.
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Figure 24. Eight C57 male mice were given 10% w/v sucrose solution in both bottles for
one month. The mice were preferred drinking solution two over solution one for first two
weeks and next two week they preferred to drink solution one over solution two.

Condition 3. After that, we started giving them ethanol on one tube and sucrose in
the other via following the same experimental procedure. The ratio of sucrose and ethanol
was 10% w/v sucrose with 2% w/v ethanol. Mice preferred to drink 10% sucrose over
ethanol.
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Figure 25. Same group of mice were given 2% w/v ethanol in one tube and 10%
w/v sucrose in other tube. Consumption of 10% sucrose is higher than the 2% EtOH. There
is no preference for EtOH over sucrose.

Condition 4. In the second part of our experiment, we got some promising data
from the mice where they demonstrated a preference for EtOH and sucrose mixture
solution over water. Mice were given 2% EtOH+10%Sucrose solution together in a tube
and water in another tube for two weeks. Tubes were interchanged every other day. After
14 days of experiment, we found that mice were drank from solution 1 over solution 2.
Mice liked to drink sweetened ethanol over water.
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Figure 26. A group of eight C57 male mice were given 2% ethanol + 10% sucrose solution
in one tube and water in other tube. Consumption of 2% ethanol + 10% sucrose solution
from one tube was significantly higher than consumption of water from another tube. Mice
showed clear preference for EtOH+ 10% sucrose solution over water.

Discussion
In the first portion of the experiment, we used eight adult C57 male mice. We fixed
the initial housing conditions for mice which included a large water bottle on one top side
of the cage for liquid consumption. Here, we observed that the mice were not interested or
previously learned to drink from the specific bottle we used to give them solutions. Hence,
they started to lose their body weight because of dehydration. To fix this issue, we provided
them with 10% w/v sucrose solution over one month and thankfully they started drinking
sucrose solution at that point.
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In the second portion of our experiment, we used the same group of mice and
observed no significant effect or preference for 2% w/v EtOH over water, rather they
preferred 10% sucrose solution. Then we increased the concentration of EtOH and
decreased the concentration of sucrose, but still there was no significant preference for
EtOH. Then we decided to start with a new set of mice who had never experienced the
standard housing conditions with one regular water bottle. The new set of mice received
2% EtOH and 10% sucrose together in one tube and water in the other tube where they
showed clear preference for 2% EtOH and 10% sucrose mixture solution over water.
Two bottle choice preference tests have been used for different types of
experiments so far, with different research interests. A study conducted by Ronald R. Ulm
demonstrated that sweetened ethanol is preferable for rats than water (Stromberg et al.,
1997). Selena E. Bartlett’s lab has conducted a study that stated, social and environmental
experiences in alcohol and sucrose consumption are critical for generating preventative
actions and treatment options for AUDs and obesity (Holgate et al., 2017).
Further investigation process of our experiment was cut short due to outbreak of
the COVID-19 pandemic though we had planned to test whether PSNCBAM-1 (CB1
negative allosteric modulator) or L-745,870 (dopamine D4 receptor antagonist) altered
patterns of ethanol consumption in the 2-bottle choice procedure.
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